Pfizer and Moderna have received billions from the COVID-19 booster vaccine market.
In 2021 and 2022, Pfizer, along with its German partner BioNTech and Moderna (MRNA.O), together blocked more than $ 60b in vaccine sales, as well as billions of dollars as potential accelerators.
In 2021 and 2022, Pfizer, along with its German partner BioNTech and Moderna (MRNA.O), together blocked more than $ 60b in vaccine sales, as well as billions of dollars as potential accelerators.
Pfizer / BioNTech will generate more than $ 6.6 billion in revenue and $ 7.6 billion for Moderna in 2023, mostly from booster sales. Pfizer and Moderna may have a lot of power over their booster prices, at least in the beginning, until competitors emerge.
Pfizer originally charged $ 19.50 per dose for its vaccine in the US and € 19.50 for the European Union but has already increased those prices by 24% and 25%, respectively, in subsequent supply deals, RTRS.
Going into details, some early evidence suggests that Moderna, which delivers a higher dose initially, maybe more durable than Pfizer.
AstraZeneca Plc and Johnson & Johnson are collecting additional data on their vaccine boosters. Novavax, Curevac, and Sanofi can also potentially be used as boosters, although their vaccines have not yet received any regulatory approval.
Titan.
Titan.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
